| 2020 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | 조병철 | Article |
| 2020 | Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study | 조병철 | Article |
| 2020 | Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
| 조병철 | Article |
| 2019-12 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study | 김혜련, 조병철, 홍민희 | Article |
| 2019 | Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models | 조병철, 표경호 | Article |
| 2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| 김민환, 김혜련, 박채원, 심효섭, 윤미란, 조병철, 표경호, 홍민희 | Article |
| 2019 | Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing | 김상우, 김혜련, 조병철, 홍민희 | Article |
| 2019 | Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
| 김혜련, 안병철, 윤미란, 조병철, 표경호, 홍민희 | Article |
| 2019 | Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study | 조병철 | Article |
| 2019 | Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer | 김시내, 김혜련, 박주영, 변화경, 윤홍인, 이창걸, 조병철, 조연아, 조재호, 홍민희 | Article |
| 2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | 김혜련, 박성용, 심효섭, 이창영, 정인경, 조병철, 차윤진, 최은아, 홍민희 | Article |
| 2019 | Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer | 김혜련, 박성용, 심효섭, 안병철, 윤홍인, 이진구, 이창영, 조병철, 표경호, 홍민희 | Article |
| 2019 | Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors | 강은석, 김규리, 김혜련, 이병완, 이용호, 조병철, 차봉수, 홍민희 | Article |
| 2019 | Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection
| 김은경, 윤선옥, 조병철, 조윤아 | Article |
| 2019 | A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs | 김혜련, 조병철, 홍민희 | Article |
| 2019 | Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
| 김상우, 김혜련, 조병철 | Article |
| 2019 | Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
| 김혜련, 박성용, 심효섭, 안병철, 윤홍인, 이창영, 조병철, 표경호, 홍민희 | Article |
| 2019 | YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer | 김혜련, 조병철, 표경호, 홍민희 | Article |
| 2019 | Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset | 조병철 | Article |
| 2019 | The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer | 김혜련, 윤홍인, 정인경, 조병철 | Article |
| 2019 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial | 조병철 | Article |
| 2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | 조병철 | Article |
| 2019 | Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer | 조병철 | Article |
| 2019 | Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
| 김가민, 김혜련, 라선영, 박성용, 심효섭, 윤홍인, 이진구, 정경영, 조남훈, 조병철 | Article |
| 2019 | High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma
| 김대준, 김혜련, 박성용, 신성관, 신수진, 조병철, 홍민희 | Article |
| 2019 | Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node Metastasis | 고윤우, 김은경, 윤선옥, 조병철 | Article |
| 2019 | Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity | 김은경, 윤선옥, 조병철 | Article |
| 2019 | NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma
| 고윤우, 윤선옥, 조병철 | Article |
| 2019 | Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
| 조병철 | Article |
| 2019 | Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate | 김대준, 김혜련, 박성용, 백효채, 서지원, 송승환, 이진구, 이창영, 정경영, 조병철, 홍민희 | Article |
| 2019 | Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer | 김경아, 김상우, 심효섭, 이창영, 조병철 | Article |
| 2019 | Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
| 김지형, 김혜련, 안병철, 조병철, 허수진, 홍민희 | Article |
| 2019 | Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma | 김혜련, 박성용, 심효섭, 이창영, 조병철, 홍민희 | Article |
| 2018 | Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors | 조병철 | Article |
| 2018 | Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | 조병철 | Article |
| 2018 | Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors | 조병철 | Article |
| 2018 | Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
| 조병철 | Article |
| 2018 | Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice | 김혜련, 안병철, 조병철, 홍민희 | Article |
| 2018 | Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. | 김혜련, 심효섭, 조병철, 표경호, 홍민희 | Article |
| 2018 | ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma | 강한나, 김혜련, 윤미란, 조병철, 홍민희 | Article |
| 2018 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation | 김대준, 김진아, 김혜련, 박성용, 백순명, 심효섭, 윤미란, 이진구, 이한나, 조병철, 표경호, 홍민희 | Article |
| 2018 | A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer | 금기창, 김다희, 김세헌, 김혜련, 조남훈, 조병철 | Article |
| 2018 | Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck | 고윤우, 김진아, 김혜련, 윤선옥, 조병철, 최은창, 홍민희 | Article |
| 2018 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study | 조병철 | Article |
| 2018 | Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions | 조병철 | Article |
| 2018 | Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies | 조병철 | Article |
| 2018 | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
| 조병철 | Article |
| 2017 | Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer | 김혜련, 심효섭, 조병철, 차윤진 | Article |
| 2017 | Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition | 김은경, 김한상, 신상준, 정기양, 정민규, 조병철 | Article |
| 2017 | A randomized; phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8; pg 15943; 2017)
| 김주항, 김혜련, 정인경, 조병철 | Article |
http://orcid.org/0000-0002-5562-270X
(Yonsei Health Research Network)
(7401747804)
